Workflow
圣湘生物收盘下跌1.73%,滚动市盈率43.79倍,总市值125.38亿元

Core Viewpoint - Shengxiang Biotechnology Co., Ltd. is experiencing a decline in stock price while maintaining a competitive position in the medical device industry, with significant growth in revenue and net profit reported in the latest quarterly results [1][2]. Company Overview - Shengxiang Biotechnology focuses on innovative gene technology, providing integrated solutions for in vitro diagnostics, including diagnostic reagents, instruments, and third-party medical testing services [2]. - The company has achieved notable recognition, ranking in the top 100 global medical device companies for two consecutive years and receiving various national and provincial honors [2]. Financial Performance - For Q1 2025, the company reported revenue of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, up 13.22%, with a gross profit margin of 76.71% [2]. Market Position - As of August 14, the company's stock closed at 21.64 yuan, with a rolling PE ratio of 43.79, compared to the industry average of 55.76 and a median of 39.14 [1][3]. - The total market capitalization of Shengxiang Biotechnology is 12.538 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders increased to 20,629, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].